Stay updated with breaking news from Development Expenses. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-Contineum is focused on leading the Neuroscience, Inflammation and Immunology field- -Successful completion of Initial Public Offering with strong syndicate of existing and new investors- ...
06.05.2024 - Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarterOn track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced ...
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation...
NEW YORK, May 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. . Such investors are advised to contact Danielle Peyton...
02.05.2024 - KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of ...